Clinical Trials Browser

Interventional × Gefitinib × Head & Neck × Clear all

NCT01185158 2023-11-29

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Phase 2 Completed

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01185171 2023-05-11

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Phase 2 Completed

70 enrolled 11 charts

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT00509002 2017-11-24

Iressa Study in Patients With Salivary Gland Cancer

Phase 2 Completed

37 enrolled 4 charts

Salivary Gland Neoplasms

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed

27 enrolled 16 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT01405846 2016-08-19

TIDAL1

Phase 2 Terminated

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT00519077 2016-07-01

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

44 enrolled 7 charts

Carcinoma, Head and Neck Neoplasms, Neoplasms

NCT00088907 2015-05-06

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Phase 3 Terminated

270 enrolled 8 charts

Head and Neck Neoplasms

NCT00015964 2013-09-05

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00024089 2013-02-11

Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00033449 2013-01-25

Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Phase NA Completed

CNSEndocrineHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Parathyroid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

NCT00352105 2012-11-05

Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer

Phase 1/2 Completed

60 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00212108 2012-04-02

A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

Phase 1/2 Completed

Nasopharyngeal Carcinoma

NCT00083057 2012-03-15

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00206219 2011-01-27

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Phase 3 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00233636 2011-01-27

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00242762 2011-01-27

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Phase 2 Completed

Head and Neck Neoplasms

NCT00193284 2010-06-22

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Phase 2 Completed

Head and Neck Neoplasms

NCT00185835 2010-03-29

Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck

Phase 1 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00229723 2009-08-04

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

224 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT00242749 2009-04-23

IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma

Phase 2 Completed

Head and Neck Neoplasms

NCT00255476 2009-04-23

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Phase 2 Completed

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00228488 2007-12-19

Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma

Phase 2 Completed

Head and Neck Neoplasms

NCT00239304 2007-12-18

Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer

Phase 1/2 Completed

Head and Neck Neoplasms

NCT00195078 2007-07-20

Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms